Search Results

Innovent Biologics, Inc. provided interpretation and updates on clinical data from Mazdutide’s GLORY-1 study and its general biomedicine pipeline at an investor conference call on June 25.

Endeavor BioMedicines, Inc. today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.

Endeavor BioMedicines today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor’s continued growth and success.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life.

Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced marketing clearance from Health Canada to commercialize Pure Impact™ utilizing PlyoPulse™ EMS (“Electric Muscle Stimulation”) technology in that region.

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.

Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year.

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc. are pleased to announce a partnership aimed to impact the care of patients with late-stage colorectal cancer undergoing surgery.